877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Atypical antipsychotics

Categories

Antipsychotics (21)
Dopamine antagonists (21)
Drugs acting on the nervous system (21)
Psychoactive drugs (21)
Psychopharmacology (21)
Cyclic compounds (19)
Six-membered rings (13)
Aromatic compounds (12)
Pharmaceuticals (11)
Piperidines (8)
Fluoroarenes (6)
Piperazines (5)
Chloroarenes (4)
Five-membered rings (4)
Pyrrolidines (4)
Alpha blockers (3)
Antihypertensive agents (3)
Dibenzazepines (3)
Drugs acting on the cardiovascular system (3)
Drugs acting on the genito-urinary system (3)
Drugs for benign prostatic hyperplasia (3)
Heterocyclic compounds (3)
Mood stabilizers (3)
Polycyclic organic compounds (3)
Urologicals (3)
Alpha-1 blockers (2)
Alpha-2 blockers (2)
Antidepressants (2)
Antihistamines (2)
Aromatic ketones (2)
D2 antagonists (2)
D3 antagonists (2)
H1 receptor antagonists (2)
Heterocyclic compounds (4 or more rings) (2)
Psychoanaleptics (2)
Antiparkinsonian agents (1)
D2-receptor agonists (1)
D3 receptor agonists (1)
Dopamine agonists (1)
Ethers (1)
GHB (1)
GHB receptor ligands (1)
Halides (1)
Heterocyclic compounds (bridged-ring) (1)
Monoamine reuptake inhibitors (1)
Nervous system drug (1)
Norepinephrine reuptake inhibitors (1)
Organobromides (1)
Organohalides (1)
Pyridines (1)
Spiro compounds (1)
Ureas (1)

Suppliers

Sigma Aldrich (8)
AK Scientific (7)
TCI Chemicals (7)
Matrix Scientific (4)
Oakwood Chemical (2)
Toronto Research Chemicals (2)
Accela (1)

Aripiprazole (129722-12-9)  
Aripiprazole, sold under the brand name Abilify among others, is an atypical antipsychotic. From April 2013 to March 2014, sales of Abilify amounted to almost $6.9 billion.. It is recommended by some doctors and used in the treatment of schizophrenia and bipolar disorder.
Asenapine (65576-45-6)  
ORG 5222  ·  saphris  ·  asenapine maleate
Asenapine, sold under the trade names Saphris and Sycrest, is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder. It was chemically derived via altering the chemical structure of the tetracyclic (atypical) antidepressant, mianserin.
Risperidone (106266-06-2)  
Risperidone, sold under the trade name Risperdal among others, is an antipsychotic medication. It is mainly used to treat schizophrenia, bipolar disorder, and irritability in people with autism. It is taken either by mouth or by injection into a muscle.
Paliperidone (144598-75-4)  
Paliperidone, sold under the trade name Invega among others, is a dopamine antagonist and 5-HT2A antagonist of the atypical antipsychotic class of medications. It is marketed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once-daily dosing.
Lurasidone (367514-88-3, 367514-87-2)  
Lurasidone (trade name Latuda) is an atypical antipsychotic developed by Dainippon Sumitomo Pharma and marketed by Sunovion in the U.S. It has been an FDA approved treatment for schizophrenia since 2010 and for treating depressive episodes in adults with bipolar I disorder since 2013. It can be used alone or in combination with mood stabilizers such as lithium or valproate (e.g., Depakote).
Iloperidone (133454-47-4)  
Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.
SERTINDOLE (106516-24-9)  
Sertindole (brand names: Serdolect and Serlect) is an antipsychotic medication. Sertindole was developed by the Danish pharmaceutical company Lundbeck and marketed under license by Abbott Labs. Like other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain.
Remoxipride (80125-14-0)  
Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.
Sultopride (53583-79-2)  
Solian  ·  amisulpride  ·  DAN 2163
Sultopride (trade names Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia. It was launched by Sanofi-Aventis in 1976. Sultopride acts as a selective D2 and D3 receptor antagonist.
Bifeprunox (350992-10-8)  
Bifeprunox (INN) (code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D2 receptor agonism with serotonin receptor agonism. It was under development for the treatment of schizophrenia but has since been abandoned. Bifeprunox has a novel mechanism of action.
zotepine (26615-21-4)  
Zotepine (brand names: Losizopilon (JP), Lodopin (ID, JP), Setous (JP), Zoleptil (CZ, PT, TR, UK†); where † indicates a formulation that has been discontinued) is an atypical antipsychotic drug indicated for acute and chronic schizophrenia. It has been used in Germany since 1990 (although it has been discontinued in Germany) and Japan since 1982. Zotepine is not approved for use in the United States, United Kingdom, Australia, Canada or New Zealand.
tiapride (51012-32-9)  
Tiapride Hydrochloride  ·  Tiaprizal  ·  Tiapride Monohydrochloride
Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly. A derivative of benzamide, tiapride is chemically and functionally similar to other benzamide antipsychotics such as sulpiride and amisulpride known for their dopamine antagonist effects.
MELPERONE (3575-80-2)  
Melperone (Bunil (PT), Buronil (AT, BE, CZ, DK, FL†, NL†, NO†, SE), Eunerpan (DE)) is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. It first entered clinical use in 1960s.
Blonanserin (132810-10-7)  
Blonanserin, sold under the brand name Lonasen, is a relatively new atypical antipsychotic (approved by PMDA in January 2008) commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics such as haloperidol.
Clothiapine (2058-52-8)  
Entumine  ·  clotiapine
Clotiapine (Entumine) is an atypical antipsychotic of the dibenzothiazepine chemical class. It was first introduced in a few European countries (namely, Belgium, Italy, Spain and Switzerland), Argentina, Taiwan and Israel in 1970. Some sources regard clotiapine as a typical antipsychotic rather than atypical due to its high incidence of extrapyramidal side effects compared to the atypicals like clozapine and quetiapine, to which it is structurally related.
nemonapride (75272-39-8)  
Nemonapride (エミレース, Emilace (JP)) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist.
Clocapramine (47739-98-0, 28058-62-0)  
Y-4153  ·  3-chlorocarpipramine  ·  3-chlorocarpipramine dihydrochloride
Clocapramine (Clofekton, Padrasen), also known as 3-chlorocarpipramine, is an atypical antipsychotic of the imidobenzyl class which was introduced in Japan in 1974 by Yoshitomi for the treatment of schizophrenia. In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic. Clocapramine has been reported to act as an antagonist of the D2, 5-HT2A, α1-adrenergic, and α2-adrenergic receptors, and does not inhibit the reuptake of either serotonin or norepinephrine.
Emonapride (70325-83-6)  
YM 09151-M  ·  YM-09151-2  ·  nemonapride
Nemonapride (エミレース, Emilace (JP)) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist.
carpipramine (5942-95-0)  
carbadipimidine  ·  carpipramine dihydrochloride  ·  Prazinil
Carpipramine (Prazinil, Defekton) is an atypical antipsychotic used for the treatment of schizophrenia and anxiety in France and Japan. In addition to its neuroleptic and anxiolytic effects, carpipramine also has hypnotic properties. It is structurally related to both tricyclics like imipramine and butyrophenones like haloperidol.
Mosapramine (89419-40-9)  
3-chloro-5-(3-(2-oxo-1,2,3,5,6,7,8,8a-octahydroimidazo(1,2-a)pyridine-3-spiro-4'-piperidino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine  ·  Y 516  ·  Y-516
Mosapramine (Cremin) is an atypical antipsychotic used in Japan. It is a potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors, and with moderate affinity for the 5-HT2 receptors.
Next Page >